Anna Rose Welch articles

  1. A Possible “Humirageddon:” Perspectives On The EU Biosimilar Launch
    10/16/2018

    In the wake of the arrival of Humira biosimilars in the EU, Jorge Santos da Silva and Jennifer Heller of McKinsey & Company share several critical pricing and market considerations for companies as this highly anticipated product finally becomes available to patients.

  2. Biosimilars, Biobetters, Or Both?: Report Highlights Manufacturing Considerations
    10/10/2018

    I sat down with Kate Hammeke, VP of Industry Standard Research to discuss the biggest surprises or takeaways from this year’s report about the industry’s biologics and biosimilars manufacturing goals. But the conversation also evolved to some of the larger trends Hammeke expects to see impacting the biosimilar players in the future.

  3. The Humira Tsunami Cometh: What Can We Expect?
    10/9/2018

    In the first segment of this two-part Q&A article, da Silva and Heller share their perspectives on the EU market potential for Humira biosimilars, which markets they expect will be most dynamic from a competition standpoint, and what Humira biosimilar players can learn from previous tumor necrosis factor (TNF) biosimilar launches.

  4. Biosimilar Education: The Elements Of An Effective Strategy
    9/28/2018

    In this first of what I expect will be several articles, I will lay out one of the current educational gaps I’ve noticed, as well as introduce real educational examples or efforts I’ve encountered (or would like to see more of) that show promising and widely adaptable pathways forward.

  5. Off The Beaten Path: 3 Strategies For Improving World-Wide Biosimilar Access
    9/28/2018

    Low- and middle-income nations naturally demand different approaches, and, there is, of course, still much work to be done to bolster biologics use in these countries. This article continues that discussion, illuminating several specific strategies companies can explore to better reach a wide variety of countries and patients.

  6. Charting A Biosimilar Course In Low- And Middle-Income Nations
    9/26/2018

    Though entering some of these nations will not be for the faint of heart, Iyer believes the solution to these access issues is closer than we realize.

  7. How Can We Make FDA’s Biosimilar Action Plan A Game-Changer?
    9/17/2018

    Despite all the FDA’s efforts to increase review time and get products to market more quickly, I remain unconvinced that the BAP will turn around the U.S. market — at least not our current market. So what can we do in the meantime?

  8. 4 Revelations From The FDA’s Biosimilar Part 15 Hearing
    9/11/2018

    In addition to laying out some of the concerning themes that came up throughout the hearing, I will unpack some of the FDA’s lines of inquiry which I feel illuminated the agency’s efforts to challenge certain claims for the first time. 

  9. Biosimilar Access: Is The Industry Overlooking Critical Markets?
    9/11/2018

    Though there’s much to write about the successes and pitfalls in the European, U.S., and Canadian biosimilar markets, it turns out there’s quite a bit that biosimilar makers need to learn about the countries off the beaten market-access path. And in many of these nations, the capacity for a biologics market already exists.

  10. What Brazil Can Learn From Denmark’s Biosimilar Policies
    8/30/2018

    In this article I continue to outline some of the Brazil Ministry of Health's biggest questions about post-market surveillance, big data, and procurement, as these are particularly telling of how the nation’s biosimilar policy could take shape in the future.